Join Growin Stock Community!

Alkermes plcALKS.US Overview

US StockHealthcare
(No presentation for ALKS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ALKS AI Insights

ALKS Overall Performance

ALKS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALKS Recent Performance

-0.65%

Alkermes plc

0.05%

Avg of Sector

-0.31%

S&P500

ALKS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ALKS Key Information

ALKS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ALKS Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Price of ALKS

ALKS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALKS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.46
PE Ratio (TTM)
14.98
Forward PE
16.40
PS Ratio (TTM)
3.37
PB Ratio
2.93
Price-to-FCF
10.22
METRIC
VALUE
vs. INDUSTRY
Gross Margin
86.69%
Net Margin
16.37%
Revenue Growth (YoY)
-5.25%
Profit Growth (YoY)
-2.50%
3-Year Revenue Growth
8.07%
3-Year Profit Growth
10.51%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.46
PE Ratio (TTM)
14.98
Forward PE
16.40
PS Ratio (TTM)
3.37
PB Ratio
2.93
Price-to-FCF
10.22
Gross Margin
86.69%
Net Margin
16.37%
Revenue Growth (YoY)
-5.25%
Profit Growth (YoY)
-2.50%
3-Year Revenue Growth
8.07%
3-Year Profit Growth
10.51%
  • When is ALKS's latest earnings report released?

    The most recent financial report for Alkermes plc (ALKS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALKS's short-term business performance and financial health. For the latest updates on ALKS's earnings releases, visit this page regularly.

  • Where does ALKS fall in the P/E River chart?

    According to historical valuation range analysis, Alkermes plc (ALKS)'s current price-to-earnings (P/E) ratio is 21.41, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ALKS?

    According to the latest financial report, Alkermes plc (ALKS) reported an Operating Profit of 58.1M with an Operating Margin of 15.11% this period, representing a decline of 64.29% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ALKS's revenue growth?

    In the latest financial report, Alkermes plc (ALKS) announced revenue of 384.55M, with a Year-Over-Year growth rate of -10.57%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does ALKS have?

    As of the end of the reporting period, Alkermes plc (ALKS) had total debt of 70M, with a debt ratio of 0.03. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ALKS have?

    At the end of the period, Alkermes plc (ALKS) held Total Cash and Cash Equivalents of 1.12B, accounting for 0.45 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ALKS go with three margins increasing?

    In the latest report, Alkermes plc (ALKS) achieved the “three margins increasing” benchmark, with a gross margin of 88%%, operating margin of 15.11%%, and net margin of 12.8%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ALKS's profit trajectory and future growth potential.

  • Is ALKS's EPS continuing to grow?

    According to the past four quarterly reports, Alkermes plc (ALKS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALKS?

    Alkermes plc (ALKS)'s Free Cash Flow (FCF) for the period is 171.14M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 5.25% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ALKS?

    The latest valuation data shows Alkermes plc (ALKS) has a Price-To-Earnings (PE) ratio of 21.41 and a Price/Earnings-To-Growth (PEG) ratio of -0.58. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.